We report the emergence of colistin resistance in Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae after 8 days of colistin-based therapy, resulting in relapse of bloodstream infection and death. Disruption of the mgrB gene by insertion of a mobile genetic element was found to be the mechanism, which was replicated in vitro after exposure to subinhibitory concentrations of colistin and meropenem.
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Carbapenem-resistant Klebsiella pneumoniae, commonly mediated in the United States by production of Klebsiella pneumoniae carbapenemase (KPC), is a cause of difficult-to-treat infections associated with high mortality. Among the only currently available agents with reliable activity against KPC-producing K. pneumoniae are polymyxin B, colistin, and combinations containing novel inhibitors of KPC that restore the activity of β-lactams. Therefore, reports describing the decreased activity of ceftazidime-avibactam, one of the combinations, and the emergence of resistance to colistin in KPC-producing K. pneumoniae are of special concern [1, 2] . Although the plasmid-mediated mcr genes are increasingly reported as a cause of colistin resistance in Escherichia coli, the most common mechanism of colistin resistance in K. pneumoniae is insertional inactivation of the mgrB gene [1] . The temporal pace and factors leading to colistin resistance through this mechanism are unknown. We report a case of a 52-year-old man (Figure 1 ) with neutropenia and chronic myelogenous leukemia who developed a central line-associated bloodstream infection with KPCproducing K. pneumoniae. The organism (isolate 1, Kpn918) had decreased ceftazidime-avibactam susceptibility in the absence of previous treatment with that agent. Despite removal of the line and 8 days of combination therapy with meropenem, tigecycline and colistin (loading dose of 5 mg/kg ideal body weight, followed by 1.75 mg/kg every 12 hours, adjusting for a creatinine clearance <50 mL/min), he relapsed with colistin-resistant KPC-K. pneumoniae bloodstream infection (isolate 2, Kpn926) and died from the infection in the setting of persistent neutropenia.
METHODS
To define the molecular mechanism of treatment-emergent colistin resistance and characterize the genetic background and evolution of colistin resistance, we performed the following microbiological tests. Antibiotic susceptibility testing was performed with disc diffusion assay and broth microdilution. In the case of colistin, broth macrodilution was performed in triplicate [3] . Results were interpreted according to Clinical and Laboratory Standards Institute guidelines, except for tigecycline and colistin minimum inhibitory concentrations (MICs), which were interpreted according to guidelines from the European Committee on Antimicrobial Susceptibility Testing [4, 5] . Multilocus sequence typing (MLST), wzi sequencing, and repetitive sequence-based polymerase chain reaction (rep-PCR) assessed genetic relatedness. Whole-genome sequencing of the isolates Kpn918 and Kpn926 was performed using the MiSeq platform (Illumina Inc., San Diego, CA) and analyzed using ResFinder, PlasmidFinder, and BLAST [6] [7] [8] . Additionally, bla KPC , bla SHV , bla NDM , bla VIM , bla IMP , bla TEM , bla OXA-48-like , ompK35/36, mcr-1/2, and mgrB genes were queried using established PCR primers, and plasmid replicon typing with PCR was performed [9] . To better understand the evolution of colistin resistance, isolate 1 (Kpn918, colistin-susceptible) was exposed to serial passages with 0.25 µg/mL of colistin and 2 µg/mL of meropenem.
inhibition, 19 mm). In regards to colistin, isolate 1 demonstrated an MIC of 0.5 µg/mL (susceptible) while isolate 2 had an MIC of 32 µg/mL (resistant). Among antibiotic combinations tested using disc diffusion, only ceftazidime-avibactam combined with aztreonam resulted in an increased zone of inhibition (to 24 mm). Genetic analysis indicated that Kpn918 and Kpn926 belonged to ST258, contained wzi 29, and shared 98.4% similarity according to rep-PCR. Each harbored bla KPC-2 , bla SHV-2 , and bla TEM-1 . Both isolates possessed FIIK plasmids harboring bla KPC-2 on a Tn4401a transposon. Neither contained additional carbapenemase genes or mcr-1/2. IS903, a 1057 base-pair-long sequence was detected within mgrB in isolate 2 (colistin-resistant). Insertional inactivation of mgrB also occurred after 3 serial passages of isolate 1 in 0.25 µg/mL of colistin; however, a different element was found (IS4). In ompK35 and ompK36 from both isolates, we identified mutations that led to a stop codon at amino acid position 50 in ompK35, and insertions encoding glycine and aspartic acid at amino acid positions 134 and 135 in ompK36. Supplementary  Figure 1 shows the results of draft whole-genome sequencing.
DISCUSSION
This report describes the occurrence of treatment-emergent colistin-resistant KPC-K. pneumoniae after 8 days of colistin-based combination therapy and highlights important observations. First, colistin resistance emerged due to disruption of mgrB by IS903. Similar emergence of colistin resistance was previously reported after 30 days of colistin therapy due to disruptive insertion of IS4-like insertion sequence into mgrB [1] . Insertion sequences are self-transmissible elements that can integrate into and excise from the chromosomes. The strain of K. pneumoniae infecting this patient belongs to ST258, the most common strain of KPC-producing K. pneumoniae in the United States and other countries, and insertional events may represent the genetic basis of its success [10, 11] . We hypothesize that this strain is prone to random transposition of insertion sequences, explaining the variability in insertion sequences found in isolate 2 in vitro during exposure to subinhibitory concentrations of colistin. The cause of transposition of insertion sequences is not known, although exposure to subinhibitory concentrations of antibiotics may be associated with such events, as reproduced in vitro in the original isolate. Antibiotic-induced bacterial stress responses can lead to insertional mutations that contribute to methicillin resistance in Staphylococcus aureus and to deletions of regulatory genes in E. coli resistant to fluoroquinolones [12, 13] . Second, we found that the porin genes ompK35 and ompK36 in both isolates contained mutations previously linked to reduced susceptibility to ceftazidime-avibactam and carbapenems [2] . Of note, our patient had not been treated with ceftazidime-avibactam; therefore, reinfection with a new strain or horizontal gene transfer from a strain previously exposed to ceftazidime-avibactam cannot be dismissed. Approximately 5 cases of carbapenem-resistant K. pneumoniae occur at our hospital monthly. Although analyses of genetic relatedness suggest that both isolates from this case are clonally related, genome sequencing of KPC-producing K. pneumoniae from our hospital reveal that highly similar subpopulations can coexist over time, including isolates containing bla KPC-2 in IncFIIK plasmids, as in this patient [14] . In conclusion, clinicians should strongly suspect emergence of resistance to colistin during treatment with colistin-based combination therapies in patients with persistent or relapsing KPC-K. pneumoniae bloodstream infection. These observations highlight the dynamic nature of resistance to colistin, often a "last-line agent" in critically ill patients.
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